Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions

Objective

Highly active antiretroviral therapy is effective at controlling HIV-1 replication, however emergence and transmission of drug-resistant viruses is increasing, including viruses resistant to the newly developped integrase catalytic inhibitors. It is essential that new antiretrovirals (ARVs) become available. Most ARVs in development belong to the classes of viral enzyme inhibitors. Since HIV requires cellular cofactors for its replication cycle, we aim to develop novel classes of ARVs inhibiting specific virus-host interactions. Because host cell factors mutate rarely, this new class of ARVs should be less vulnerable to resistance. We selected two cellular targets, LEDGF/p75 and Transportin-SR2 (Trn-SR2), cofactors of Integrase (IN) and Capsid (CA) respectively, important for viral integration and nuclear transport. Partners of this consortium, R. Benarous, P. Cherepanov, A. Fassati and S. Emiliani, discovered, with others, these targets and elucidated their structure and function. Partner 1 SME BIODIM (FR), consortium leader, has developped small compound inhibitors of IN-LEDGF interaction. BIODIM compounds have a clear structure activity relationship, nanomolar ARV activity and are based on a new, structurally defined pharmacophore. The objectives of this project are to 1) Advance BIODIM IN-LEDGF inhibitors up to the proof of concept (POC) in man in a phase I/IIa clinical trial with partner 6 J. Gatell (SP) 2) Discover small compounds targeting the Trn-SR2 pathway in HIV-1 infection using a high throughput screening assay validated by partner 2 A. Fassati (UK), determine the pharmacophore by solving the 3D structure of Trn-SR2 with partner 3 P. Cherepanov (UK) and optimize the compounds up to the POC in a humanized mouse model of HIV infection with partner 5, B. Berkhout (NL) 3) Elucidate with partner 4 Emiliani/Saïb (FR) the network of interactions in which Trn-SR2 is involved with CA from uncoating to the pre-integration complex to provide new ARV drug targets.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

LABORATOIRE BIODIM
EU contribution
€ 3 909 631,00
Address
RUE DE GRENELLE 84
75007 PARIS
France

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (6)

My booklet 0 0